The role of pemetrexed in recurrent epithelial ovarian cancer: a scoping review

Oncology Reviews

卷:12

Linda Li¹  Michael Roche¹  Laura Parisi²  Rebecca Phaeton³  Joshua P. Kesterson³  Amy Knehans⁴ 

[1] Department of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania;

[2] Department of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas;

[3] Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania;

[4] Harrell Health Sciences Library, Penn State College of Medicine, Hershey, Pennsylvania;

关键词: Pemetrexed;    Alimta;    recurrent epithelial ovarian cancer;    Fallopian tube cancer;    primary peritoneal cancer;   

DOI  :  10.4081/oncol.2018.346

来源: DOAJ

【 摘 要 】

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaTM) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

【 授权许可】

Unknown